

SEARCH
QUICKLINKS AND VIEW OPITONS
Richard Bartlett, MD treating Covid-19 with an inhaled steroid, budesonide
Posted by .(JavaScript must be enabled to view this email address)
Monday, July 13, 2020 6:28 pm Email this article
Here is an interesting 3-minute video clip of Richard Bartlett, MD from Texas talking about treating Covid-19 patients with an inhaled steroid (budesonide, Pulmicort) — he has patients use it in a nebulizer — plus the antibiotic, clarithromycin (Biaxin) plus zinc.
He says that Taiwan, which has had only 7 deaths from Covid-19, Singapore, which has had only 26 deaths from Covid-19, and Japan, which has had only 982 deaths from Covid-19, are all using inhaled steroids to treat patients with Covid-19.
He says that none of his patients have died, but unfortunately he does not say how many Covid-19 patients that he has treated.
He says the NIH, Oxford University, France and Spain, are all going to do studies of giving inhaled budesonide for Covid-19, but he says that the NIH study is set up for failure because they are only going to give it when patients are severely ill (with pneumonia, in the ICU and on a ventilator).
The dosages he is using, as noted in the report linked below, are as follows:
- budesonide 0.5mg nebulizer twice daily
- clarithromycin (Biaxin) 500mg tab twice daily for ten days
- Zinc 50mg tab twice daily
- aspirin 81mg tab daily
He also notes in the interview that hydroxychloroquine works, but they took it away from him early so he had to come up with another treatment for Covid-19 patients.
The entire 30-minute interview is posted here:
https://www.youtube.com/watch?v=eDSDdwN2Xcg
Here is his contact info:
Richard P. Bartlett, MD
1330 E 8th St
Odessa, TX, 797613
(432) 631-2178
.(JavaScript must be enabled to view this email address)
A report written by Dr. Barlett about using this treatment is posted here.
Articles on the same subject can be found here:
COMMENTS
Please feel free to share your comments about this article.
© Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.